This infographic explores the handling requirements of CGTs and how an experienced CDMO partner can ensure quality at the fill/finish step. Cell and gene therapies (CGTs) hold extraordinary promise, but also present unique manufacturing challenges. In particular, fill/finish must occur in a purpose-built, isolated, highly controlled environment to ensure consistent quality in every dose. CGTs with viral vector requirements add more complexity to drug product manufacturing. An expert CDMO can support viral vector CGTs from preclinical promise to commercial success. This infographic explores the handling requirements of CGTs and how an experienced CDMO partner can help minimize contamination, product loss, and process variability. The fill/finish step is critical to CGT safety and efficacy. Highlights include: The unique characteristics that differentiate CGTs from traditional biologics. Ten components of a purpose-built CGT fill/finish suite that drive quality at every phase. What an expert viral vector CDMO brings to the table in experience, capabilities, and equipment and facilities.
